Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Apellis Pharmaceuticals
Thumbnail
July 21, 2022

Vertex gets more in vivo gene editing Verve

Thumbnail
March 16, 2022

Apellis gets a long-term boost

Article image
Vantage logo
December 22, 2021

Novartis eyes up another gene therapy

The company is making a high-risk, high-reward bet with the purchase of Gyroscope.

Article image
Vantage logo
November 29, 2021

Biggest unpartnered assets: Argenx nears crunch time

Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.

Article image
Vantage logo
October 04, 2021

Global pharma stocks struggle in the third quarter

A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.

Article image
Vantage logo
September 16, 2021

Biogen leads the amyotrophic lateral sclerosis hopefuls

Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.

Article image
Vantage logo
September 10, 2021

Apellis finds that one of its twins is evil

A hit and a miss with pegcetacoplan in late-stage trials leaves Apellis with shrinking prospects.

Article image
Vantage logo
June 30, 2021

Biotech’s important upcoming data

Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.

Article image
Vantage logo
June 23, 2021

No land grab for Gemini in geographic atrophy

Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.

Article image
Vantage logo
June 02, 2021

US FDA approval tracker: May 2021

Article image
Vantage logo
May 17, 2021

Apellis crosses the finish line – now to pay it back

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 15, 2022

Q2 Roundp Medtech Infographic

August 12, 2022

Q2 Roundup Pharma Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.

Open modal